Nihar Bhowmik, MD
Internal Medicine · Portsmouth, VANPI 1134173396
Payments from drug & device makers
Across 96 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$232
- Amgen$227
- Boehringer Ingelheim$179
- Pfizer$172
- Novo Nordisk$77
- Novartis$65
- plus $579 from 19 others
What the payments were for
- Food & beverage$1,531100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $232 |
| Amgen | 14 | $227 |
| Boehringer Ingelheim | 12 | $179 |
| Pfizer | 10 | $172 |
| Novo Nordisk | 5 | $77 |
| Novartis | 4 | $65 |
| Astellas Pharma US Inc | 4 | $62 |
| GSK | 3 | $61 |
| AbbVie | 4 | $57 |
| UCB, Inc. | 3 | $53 |
| Dexcom, Inc. | 3 | $47 |
| Sunovion Pharmaceuticals Inc. | 3 | $43 |
| Johnson & Johnson | 3 | $40 |
| Global Blood Therapeutics, Inc. | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $31 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Mylan Specialty L.p. | 1 | $17 |
| Corcept Therapeutics | 1 | $17 |
| Merck | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Abbott | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
How this compares
$1,531 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 130 | $103,557 |
| EliquisApixaban | 89 | $73,493 |
| JanuviaSitagliptin Phosphate | 63 | $52,530 |
| OzempicSemaglutide | 19 | $28,978 |
| LinzessLinaclotide | 29 | $16,506 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $14,615 |
| Colchicine | 72 | $12,979 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 121 | $12,447 |
| EntrestoSacubitril/Valsartan | 19 | $11,988 |
| TradjentaLinagliptin | 12 | $9,824 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $9,187 |
| XareltoRivaroxaban | 15 | $8,336 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 301 | $7,997 |
| MyrbetriqMirabegron | 15 | $7,737 |
| CreonLipase/Protease/Amylase | 11 | $7,513 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $179 | $118,866153 claims |
| PfizerEliquis | $172 | $73,49389 claims |
| MerckJanuvia | $15 | $52,53063 claims |
| Novo NordiskOzempic | $77 | $28,97819 claims |
| AbbVieLinzess, Creon, Synthroid | $57 | $25,71965 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $61 | $19,34734 claims |
| NovartisEntresto | $65 | $11,98819 claims |
| AstraZenecaSymbicort | $232 | $9,18734 claims |
| Johnson & JohnsonXarelto | $40 | $8,33615 claims |
| Astellas Pharma US IncMyrbetriq | $62 | $7,73715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Portsmouth
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
- Sue BrownCharlottesville$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.